RATiFY is a non-randomised,multicentre,phase II trial. Eighty patients will be recruited and,following initial treatment with 3 cycles of tislelizumab and PET-CT with ceCT scan,will be assigned to 1 of 5 treatment groups (Groups A to E) based on disease stage,risk,and response. Patients with early stage lymphoma showing good response (Group A) will receive radiotherapy and further tislelizumab for up to 2 years,but no chemotherapy. All other patients (Groups B-E) will receive further tislelizumab with AVD chemotherapy for between 2 and ...

GO TO STUDY

PEARLS is a 2-arm,parallel-group,individually randomised,open label assessor-blinded,multicentre,superiority trial with an internal pilot phase. It is a pragmatic trial and the trial participants in both intervention and comparator group will receive commonly prescribed topical corticosteroids (TCSs),which is tailored for the participant. The only difference between the treatment groups is the treatment regimen/strategy. There are number of TCS products available on the market and all available brands and forms can be prescribed to participants. Participants will be randomised to one of ...

GO TO STUDY

ADVANCE is a longitudinal cohort study supporting scientific research by members of the 'NASH Disease Translational Accelerator' (NASH-DTA) Consortium. The overarching aim is to leverage a greater understanding of disease pathophysiology to develop robust methods for diagnosis, risk stratification and therapy for patients with Non-Alcoholic Fatty Liver Disease related advanced liver fibrosis/cirrhosis (“compensated advanced chronic liver disease, cACLD”). To achieve this we will assemble a longitudinal observational cohort of well-characterised patients with Non-Alcoholic Fatty Liver Disease (NAFLD) related advanced liver ...

GO TO STUDY

This is a phase IIIa,multi-centre,randomised,doubled-blind,parallel-group,placebo-controlled trial,with a 104-week blinded treatment period followed by a 26-week open-label extension. The aim of the trial is to assess whether 1260mg of ambroxol daily can slow down the progression of Parkinson’s disease (PD),in comparison to a matching placebo,and to establish the safety of long-term use of ambroxol at this dose. 330 participants will be recruited from approximately 10 UK sites over a 24-month period. Data analysis will be performed by UCL CCTU’s statisticians at ...

GO TO STUDY

Reflux disease can severely impact upon quality-of-life and lead to complications, including ulceration of the oesophagus. It is often controlled with self-help measures and medication. However, sometimes surgery is recommended. The current standard surgical treatment is called a fundoplication. This operation is carried out through keyhole (laparoscopic) surgery, and tightens the lower oesophagus to prevent reflux. Fundoplication is very safe and improves the quality-of-life of most patients. However, many patients have gas bloating, difficulty swallowing and recurrence of their reflux ...

GO TO STUDY

Tuberculosis (TB) kills more people than any other single infectious disease. We really need an effective vaccine to prevent people getting TB, but we don’t understand what sort of immune response is needed to protect people. The very early responses in TB infection, is not well understood, partly because it is difficult to study as most of the changes happen before people get symptoms. This study has been designed to help to answer two key questions about the early immune ...

GO TO STUDY

This is a FTiH modular, Phase I/II, open-label, multicentre, dose escalation and expansion study in participants with r/r haematologic malignancies. The study consists of several study modules, each evaluating the safety, tolerability, PK, pharmacodynamics, and efficacy of orally administered AZD3470 as monotherapy and in combination with other anticancer agents. This study will follow a modular protocol design evaluating AZD3470 as monotherapy and in combination with other anticancer agents. New cohorts (including further monotherapy expansion) and new modules for combination treatments may be ...

GO TO STUDY

Childhood and adolescent cancers comprise a heterogeneous group of rare diseases, mostly distinct to those diagnosed in adults. Survival of children and adolescents with cancer has considerably improved in recent decades, but cancer remains the most common cause of disease-related mortality in developed countries. In the case of disease relapse, the prognosis for paediatric patients is poor with survival rates of < 20%. Better understanding of tumor biology has led to exponentially increased development of novel targeted therapies and immunotherapies in ...

GO TO STUDY

Stomach cancer is the fifth most common cancer in the UK and most (70%) of cases are diagnosed when the cancer is already at an advanced stage. Stomach cancer arises following chronic inflammation of the stomach. Helicobacter pylori (H. pylori) is a bacteria that can cause an infection in the stomach. It is very common, some people estimate that 50% of people worldwide are infected with H. pylori. For a small number of people, this infection can lead to ...

GO TO STUDY

Nemaline myopathies(NM) are genetically determined conditions that usually present with muscle weakness, breathing problems and difficultly feeding. The severity of NM varies from significant muscle weakness requiring a wheelchair, breathing and feeding support with signifcantly reduced life expectancy to milder forms in which the person remains able to walk and has a normal lifespan. Current treatments for people living with NM are supportive only. Several potential therapies are in development which may be available in the next 5-10 years. ...

GO TO STUDY